We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-4.96%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$430M
AUM Growth
-$3.15M
Cap. Flow
+$54.1M
Cap. Flow %
12.58%
Top 10 Hldgs %
94.76%
Holding
18
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$50.4M
2
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$4.72M
3
COGT icon
Cogent Biosciences
COGT
+$117K

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$1.15M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
1
Arvinas
ARVN
$524M
$151M 35.12%
2,283,048
– –
HARP
2
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$66M 15.37%
315,670
+23,529
+8% +$4.72M
DCPH
3
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$54.2M 12.62%
1,209,571
– –
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.34B
$50.5M 11.75%
+1,553,661
New +$50.4M
PASG icon
5
Passage Bio
PASG
$15.7M
$43.7M 10.16%
124,896
– –
CMRX
6
DELISTED
Chimerix, Inc.
CMRX
$11.8M 2.75%
1,224,600
-125,400
-9% -$1.15M
APTX
7
DELISTED
Aptinyx Inc. Common Stock
APTX
$9.87M 2.3%
3,290,079
– –
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$7.06M 1.64%
409,611
– –
ALEC icon
9
Alector
ALEC
$167M
$6.84M 1.59%
339,569
– –
ARAV
10
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.24M 1.45%
946,423
– –
COGT icon
11
Cogent Biosciences
COGT
$6.75B
$4.4M 1.02%
501,530
+12,150
+2% +$117K
TECX
12
Tectonic Therapeutic
TECX
$579M
$4M 0.93%
26,296
– –
CHMA
13
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.56M 0.83%
1,135,700
– –
OBSV
14
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.93M 0.68%
900,501
– –
XFOR icon
15
X4 Pharmaceuticals
XFOR
$364M
$2.88M 0.67%
11,167
– –
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$8.87B
$2.15M 0.5%
141,000
– –
ITRM
17
DELISTED
Iterum Therapeutics
ITRM
$2.05M 0.48%
97,087
– –
PDSB icon
18
PDS Biotechnology
PDSB
$38.4M
$533K 0.12%
117,242
– –

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q1 2021 Portfolio in Review

As of Q1 2021, New Leaf Venture Partners held 18 positions worth $430M, down 0.73% from $433M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

New Leaf Venture Partners deployed $54.1M of net new capital in Q1 2021, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Edgewise Therapeutics: 1,553,661 shares worth $50.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Chimerix, Inc., an estimated $1.15M trimmed.

  • New Leaf Venture Partners's largest Q1 2021 buy was Edgewise Therapeutics: 1,553,661 shares worth $50.5M.
  • New Leaf Venture Partners added most to Harpoon Therapeutics, Inc. Common Stock in Q1 2021, an estimated $4.72M increase.
  • New Leaf Venture Partners's biggest Q1 2021 reduction was Chimerix, Inc., cutting an estimated $1.15M.
  • New Leaf Venture Partners's ten largest holdings make up 95% of its $430M portfolio in Q1 2021.
  • New Leaf Venture Partners opened 1 new position and closed 0 in Q1 2021.
  • New Leaf Venture Partners's portfolio value fell 0.73% quarter-over-quarter to $430M.

Based on New Leaf Venture Partners's 13F filing for Q1 2021, filed 12 May 2021.